A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

NCT01272141 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Slow accrual, Funding stopped

Conditions

Breast Neoplasms
Breast Cancer
Cancer of the Breast

Interventions

DRUG: Lapatinib and Everolimus

Sponsor

Emory University